2. Cancer
  3. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis Related Products (43736):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N13176
    Stellettin B 184885-91-4
    Stellettin B is a triterpenoid compound that can be isolated from the marine sponge Jaspis stellifera. Stellettin B induces G1 phase arrest, apoptosis, and autophagy in human non-small cell lung cancer A549 cells by blocking the PI3K/Akt/mTOR pathway. Stellettin B can reduce the migration and invasion of liver cancer cells by decreasing the activation of the MAPK and FAK/PI3K/AKT/mTOR signaling pathways. Stellettin B can be used in the study of various tumors.
    Stellettin B
  • HY-B0656S1
    Rabeprazole-13C,d3 1261392-48-6
    Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole-<sup>13</sup>C,d<sub>3</sub>
  • HY-N5208
    YM-216391
    YM-216391 is an antitumor cyclic peptide that can be isolated from the cultured mycelium of Streptomyces nobilis JCM 4274. YM-216391 exhibits potent cytotoxic activity against a variety of human cancer cell lines and can be used in anticancer research.
    YM-216391
  • HY-12933
    BIIB-028 911398-13-5
    BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation.
    BIIB-028
  • HY-123802
    BIO7662 327613-10-5
    BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions.
    BIO7662
  • HY-47733
    CDK1/2/4-IN-2 677701-62-1
    WAY-643018 (Compound 2), an indazolecarboxamide derivative, is a CDK1, CDK2, and CDK4 inhibitor. CDK1/2/4-IN-2 has the potential for cancer research.
    CDK1/2/4-IN-2
  • HY-13673S2
    Goserelin-d7 TFA
    Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
    Goserelin-d<sub>7</sub> TFA
  • HY-W743654R
    Capsorubin (Standard) 470-38-2
    Capsorubin (Standard) is the analytical standard of Capsorubin. This product is intended for research and analytical applications. Capsorubin is a carotenoid found in peppers with multiple biological activities. Capsorubin (167 μM) inhibits lipid peroxidation induced by 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) in vitro. Capsorubin (1 μM) reduces UVB-induced DNA strand breaks and apoptosis in human dermal fibroblasts. Capsorubin also inhibits Epstein-Barr virus early antigen (EBV-EA) activation induced by phorbol 12-myristate 13-acetate in Raji cells, a marker of tumorigenesis.
    Capsorubin (Standard)
  • HY-122626
    BRPF1B/TRIM24-IN-1 1242907-48-7
    BRPF1B/TRIM24-IN-1 (compound 34) is a potent TRIM24/BRPF1/BRPF2 inhibitor, with IC50 values of 0.43, 0.34, 1.75 μM, respectively. BRPF1B/TRIM24-IN-1 binds the TRIM24 bromodomain with a KD of 222 nM and has a KD for the BRPF1 bromodomain of 137 nM and for BRD1 of 1130 nM.
    BRPF1B/TRIM24-IN-1
  • HY-158117
    [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2
    [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 (Compound 3) is a copper complex, which inhibits cell viability of HCT116, HCT116DoxR, A2780 and fibroblasts, with IC50s of 0.13, 0.15, 0.66 and 6.24 μM, respectively. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 induces apoptosis and autophagy, and arrests cell cycle at G0/G1 phase in HCT116DoxR. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 exhibits antimetastatic efficacy.
    [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2
  • HY-B1115AR
    Buspirone (Standard) 36505-84-7
    Buspirone (Standard) is the analytical standard of Buspirone. This product is intended for research and analytical applications. Buspirone is an orally active 5-HT1A receptor agonist, and a dopamine D2 autoreceptorsant antagonist. Buspirone is an anxiolytic agent, and can be used for the generalized anxiety disorder research.
    Buspirone (Standard)
  • HY-124953R
    7,3',4'-Trihydroxyisoflavone (Standard) 485-63-2
    7,3',4'-Trihydroxyisoflavone (Standard) is the analytical standard of 7,3',4'-Trihydroxyisoflavone. This product is intended for research and analytical applications. 7,3',4'-Trihydroxyisoflavone, a major metabolite of Daidzein, is an ATP-competitive inhibitor of Cot (Tpl2/MAP3K8) and MKK4. 7,3',4'-Trihydroxyisoflavone has anticancer, anti-angiogenic, chemoprotective, and free radical scavenging activities.
    7,3',4'-Trihydroxyisoflavone (Standard)
  • HY-146269
    11-Desethyl Irinotecan 103816-16-6
    11-Desethyl Irinotecan is a camptothecin (CPT) analog and one of the metabolites of irinotecan. It is promising for cancer research.
    11-Desethyl Irinotecan
  • HY-119975
    Carazostatin 126168-32-9
    Carazostatin (DC118), an antioxidant, can be isolated from Streptomycs chromofuscus. Carazostatin (DC118) exhibits strong inhibitory activity against free radical-induced lipid peroxidation and shows stronger antioxidant activity in liposomal membranes than α-tocopherol (VE).
    Carazostatin
  • HY-N9650
    Mesuagin 21721-08-4
    Mesuagin (Mammea A/AD cyclo D) shows anticancer activity and can be isolated from the Mammea americana L. seeds.
    Mesuagin
  • HY-137139
    10'-Desmethoxystreptonigrin 136803-89-9
    10'-Desmethoxystreptonigrin is an inhibitor for Ras Farnesyltransferase with an IC50 of 21 μM. 10'-Desmethoxystreptonigrin is a broad-spectrum antibiotic with antibacterial activity. 10'-Desmethoxystreptonigrin exhibits antitumor activity against P388 leukemia, without significant cytotoxicity (LD50 is 8.8 mg/kg).
    10'-Desmethoxystreptonigrin
  • HY-12177R
    Aliskiren hemifumarate (Standard) 173334-58-2
    Aliskiren (hemifumarate) (Standard) is the analytical standard of Aliskiren (hemifumarate). This product is intended for research and analytical applications. Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
    Aliskiren hemifumarate (Standard)
  • HY-137632
    Sp-8-Cl-cAMPS 142754-28-7
    Sp-8-Cl-cAMPS is an analog of cAMP (HY-B1511) and a derivative of Sp-8-Cl-cAMP. Sp-8-Cl-cAMPS inhibits the growth of human leukemia cell HL-60 and colon cancer cell LS-174T, with IC50 of 8-100 μM. Sp-8-Cl-cAMPS activates the protein kinases cAKI and cAKII, with Ka of 0.25 and 3.2 μM.
    Sp-8-Cl-cAMPS
  • HY-171207
    In vivo Jund Mouse Pre-designed siRNA-3
    In vivo Jund Mouse Pre-designed siRNA-3 is a siRNA product designed for the Jund (Mouse) gene and can be used for in vivo experiments in mice.
    In vivo Jund Mouse Pre-designed siRNA-3
  • HY-159937
    PKMYT1-IN-7 2986404-30-0
    PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and <.
    PKMYT1-IN-7